OncoRNA SA is a subsidiary of OncoDNA SA, a leading genomics and theranostics company focused on precision medicine for cancer and genetic diseases. Our mission of OncoRNA is to manufacture and commercialize Personalized RNA Cancer Immuno-Therapy (PRCIT) potentially a fast, high-performant, and cost-effective personalized immunotherapies for cancer patients. Our therapy utilizes a proprietary technology that combines small neoantigen mRNA (snmRNA) pool technology with lipid nanoparticle (LNP) technology, enabling the design of personalized mRNA cancer vaccines. By stimulating the patient's immune system to target and eliminate tumor cells based on specific mutations, OncoRNA's PRCIT offers a groundbreaking approach to cancer immunotherapy.